A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial

• Srdan Verstovsek,
• Moshe Talpaz,
• Martha Wadleigh,
• Alessandro Isidori,
• Peter te Boekhorst,
• Michael R. Savona,
• Prithviraj Bose,
• Olga Pozdnyakova,
• Ruben Mesa,
• Tarec C. El-Galaly,
• Jennifer O’Sullivan,
• Katia Gamel,
• Brian Higgins,
• Sudhakar Katakam,
• Boyan Todorov,
• Kerstin Trunzer,
• Claire N. Harrison

Affiliations

Srdan Verstovsek

The University of Texas MD Anderson Cancer Center, Houston, TX

Moshe Talpaz

Michigan Medicine - The University of Michigan, Ann Arbor, MI

Martha Wadleigh

Dana-Farber Cancer Institute, Boston, MA

Alessandro Isidori

Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy

Peter te Boekhorst

Erasmus Medical Center, Rotterdam, the Netherlands

Michael R. Savona

Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

Prithviraj Bose

The University of Texas MD Anderson Cancer Center, Houston, TX

Olga Pozdnyakova

Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Ruben Mesa

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC

Tarec C. El-Galaly

Department of Haematology, Aalborg University Hospital, Aalborg, Denmark

Jennifer O’Sullivan

Guy’s and St Thomas’ NHS Foundation Trust, London

Katia Gamel

F. Hoffmann-La Roche, Ltd., Basel

Brian Higgins

Genentech Inc, South San Francisco, CA

Sudhakar Katakam

F. Hoffmann-La Roche, Ltd., Basel

Boyan Todorov

F. Hoffmann-La Roche, Ltd., Basel

Kerstin Trunzer

F. Hoffmann-La Roche, Ltd., Basel

Claire N. Harrison

Guy’s and St Thomas’ NHS Foundation Trust, London